pKDR/KDR Ratio as Possible Predictor of Response in Phase I/II Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer
Discover our resources
Resource types
Topics
-
Download Poster pKDR/KDR Ratio as Possible Predictor of Response in Phase I/II Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer
-
Download Poster Phase 1 Trial of a Combination of the VEGFR KinaseInhibitor Cediranib(AZD2171) and Bevacizumab in Advanced Malignancies
Phase 1 Trial of a Combination of the VEGFR KinaseInhibitor Cediranib(AZD2171) and Bevacizumab in Advanced Malignancies
%20and%20Bevacizumab%20in%20Advanced%20Malignancies.jpg?width=270&height=350&name=99.%20Phase%201%20Trial%20of%20a%20Combination%20of%20the%20VEGFR%20KinaseInhibitor%20Cediranib(AZD2171)%20and%20Bevacizumab%20in%20Advanced%20Malignancies.jpg)
-
Download Poster Prospective Real-time Analysis of P-cadherin Expression to Select Patients into a Phase I Oncology Trial
Prospective Real-time Analysis of P-cadherin Expression to Select Patients into a Phase I Oncology Trial
-
Download Poster Validation of a Gliadin α-I/α-II DQ2 Tetramer Flow Cytometric Assay a Biomarker to Asess Gluten Specific T Cells in Celiac Disease
Validation of a Gliadin α-I/α-II DQ2 Tetramer Flow Cytometric Assay a Biomarker to Asess Gluten Specific T Cells in Celiac Disease
-
Download Poster An Assay to Monitor the Engagement and Modulation of CD6 on T cells as a Clinical Biomarker of Treatment with Itolizumab
An Assay to Monitor the Engagement and Modulation of CD6 on T cells as a Clinical Biomarker of Treatment with Itolizumab
-
Download Poster Validation of BTK & Aiolos Immunophenotyping Assay to Monitor B, NK & T cell Responses as a Clinical Biomarker in B-cell Malignancies
Validation of BTK & Aiolos Immunophenotyping Assay to Monitor B, NK & T cell Responses as a Clinical Biomarker in B-cell Malignancies
-
Download Poster Validation of a Whole Blood and Proteomic Stabilized Blood Assay to Monitor the Engagement and Modulation of CD6 on T cells by Itolizumab as a Clinical Pharmacodynamic
Validation of a Whole Blood and Proteomic Stabilized Blood Assay to Monitor the Engagement and Modulation of CD6 on T cells by Itolizumab as a Clinical Pharmacodynamic
-
Download Poster Evaluation of total PD-1 expression using multi-color flow cytometry in Metastatic Non-Small Cell Lung Cancer patients treated with Multi-Neoantigen Vector (ADXS-503) in
Evaluation of total PD-1 expression using multi-color flow cytometry in Metastatic Non-Small Cell Lung Cancer patients treated with Multi-Neoantigen Vector (ADXS-503) in
%20in.jpg?width=270&height=350&name=93.%20Evaluation%20of%20total%20PD-1%20expression%20using%20multi-color%20flow%20cytometry%20in%20Metastatic%20Non-Small%20Cell%20Lung%20Cancer%20patients%20treated%20with%20Multi-Neoantigen%20Vector%20(ADXS-503)%20in.jpg)
